.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Teva
AstraZeneca
Harvard Business School
Cipla
Fuji
Mallinckrodt
Citi
Queensland Health
Julphar

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,874,557

« Back to Dashboard

Details for Patent: 5,874,557

Title: Nucleic acid ligand inhibitors to DNA polymerases
Abstract:High-affinity oligonucleotide ligands to the thermostable Taq polymerase and Tth polymerase are disclosed. Specifically disclosed are DNA ligands having the ability to bind to the Taq and Tth polymerases and the methods for obtaining such ligands. The ligands are capable of inhibiting polymerases at ambient temperatures.
Inventor(s): Gold; Larry (Boulder, CO), Jayasena; Sumedha D. (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 07, 1995
Application Number:08/487,720
Claims:1. A purified and isolated non-naturally occurring nucleic acid ligand to a DNA polymerase.

2. A nucleic acid ligand to a DNA polymerase identified according to the method comprising:

a) preparing a candidate mixture of nucleic acids;

b) contacting the candidate mixture of nucleic acids with the DNA polymerase, wherein nucleic acids having an increased affinity to the DNA polymerase relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to the DNA polymerase, whereby a nucleic acid ligand of the DNA polymerase may be identified.

3. A purified and isolated non-naturally occurring nucleic acid ligand to a reverse transcriptase.

4. A nucleic acid ligand to a reverse transcriptase identified according to the method comprising:

a) preparing a candidate mixture of nucleic acids;

b) contacting the candidate mixture of nucleic acids with the reverse transcriptase, wherein nucleic acids having an increased affinity to the reverse transcriptase relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to the reverse transcriptase, whereby a nucleic acid ligand of the reverse transcriptase may be identified.

5. The purified and isolated non-naturally occurring nucleic acid ligand of claim 1, wherein said DNA polymerase is Thermus aguaticus (Taq) polymerase and wherein said ligand is selected from the group set forth in Table 3 (SEQ ID NOS:36-74).

6. The purified and isolated non-naturally occurring nucleic acid ligand of claim 1, wherein said DNA polymerase is Thermus thermophilus (Tth) polymerase, and wherein said DNA ligand is selected from the group set forth in Table (SEQ ID NOS:7-35).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Chubb
Chinese Patent Office
Covington
Harvard Business School
Federal Trade Commission
AstraZeneca
Queensland Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot